Merck and Moderna's personalized cancer vaccine data get a post-ESMO podcast review

STAT's podcast covers how oncologists reacted to detailed Merck–Moderna mRNA vaccine data shown at ESMO. The page gives no results.

STAT's Readout LOUD podcast, published Oct. 30, 2026, looks at detailed data on an mRNA cancer vaccine from Merck and Moderna. The data were presented at the European Society for Medical Oncology's annual meeting. Hosts Elaine Chen, Adam Feuerstein and Allison DeAngelis are joined by STAT colleague Andrew Joseph to discuss how doctors reacted. The episode also touches on Amgen lung cancer data and Roche results, and the hosts consider what the next big advances in oncology might be.

Why it matters for abundance: a personalized vaccine built on mRNA could add a manufacturable, scalable layer to cancer treatment. That depends on late-stage trials confirming benefit, and that framing comes from the story's blurb, not from the episode page. If the benefit holds, treatment could reach more people at lower cost.

The source is only a podcast summary page with no transcript. It gives no trial results, endpoints, patient numbers or doctor quotes, and it doesn't say what the vaccine data showed. The detail sits with STAT's episode.

Source: STAT